Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (1013)	6/1/1998 10:07:00 PM
From: Larry E Smith	Read Replies (1) \| Respond to of 2887

Anyone care to ponder on the current quarters earnings? I believe slow and steady improvement if not the same as last or last years 2Q. Not too hard to figure out I believe.

To: Jeffrey L. Henken who wrote (1013)	6/1/1998 10:13:00 PM
From: Larry E Smith	Respond to of 2887

Revised OmniCath Clinical Trial Protocol THE WOODLANDS, Texas--(BW HealthWire)--May 21, 1998--American BioMed Inc. (OTC Bulletin Board: ABMI) Thursday announced it has received Food and Drug Administration approval for a revised protocol for its Phase II OmniCath(R) Peripheral Atherectomy catheter IDE clinical trials. According to company management, the OmniCath(R) Peripheral Atherectomy clinical trials will immediately utilize the revised IDE protocols, beginning at UCLA under the direction of the company's Chief Clinical Investigator, Dr. Samuel S. Ahn, and will be expanded to ten additional sites. The clinical trials will cover 200 subjects and will take approximately 12 to 15 months to complete. Clinical trials are also expected to begin in Japan over the next 60-90 days utilizing protocols similar to U.S. requirements. Steven B. Rash, president and chief executive officer of American BioMed stated: "Upon completion of the clinical trials and final approvals from the FDA, this product will be available for sale in the U.S and Japan. This product will be addressing an estimated $100 million peripheral market and represent the first major product that we take through the FDA approval process and then to commercialization in the United States." The OmniCath(R) Peripheral Atherectomy Catheter is a cost efficient, minimally invasive approach for the removal of plaque from obstructed blood vessels which helps return normal blood flow. This product is covered by six patents and is currently marketed in Europe, South America, Central America, Asia and the Middle East. Interested investigators should contact sponsor: American BioMed, Steven Rash, President and CEO. The OmniCath(R) Peripheral Atherectomy Catheter is labeled: "Caution -- Investigational Device, Limited by Federal Law (US) to Investigational Use." American BioMed utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The company's products include 1OO%-silicone-based catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal, the OmniCath(R), an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OrniFilter, which is used to prevent blood clots from reaching various organs of the body. The company has over 25 patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the company's accounting policies, and other risks detailed in the company's Securities and Exchange Commission filings. CONTACT: American BioMed Inc. Steven B. Rash, 281/367-3895 or Coffin Communications Bill Coffin, 818/789-0100 or Coffin/Mottola Communications Christi Mottola, 714/851-1109 KEYWORD: CALIFORNIA BW1097 MAY 21,1998

To: Jeffrey L. Henken who wrote (1013)	6/1/1998 10:23:00 PM
From: Larry E Smith	Read Replies (2) \| Respond to of 2887

THE WOODLANDS, Texas--(BW HealthWire)--May 7, 1998--American BioMed Inc. (OTC Bulletin Board: ABMI), Thursday announced that the company has signed an agreement with an institutional investor that allows for American Biomed Inc. to receive up to five million dollars in an equity line of credit. According to American BioMed Inc.'s President and Chief Executive Officer Steven B. Rash, the company received $600,000 immediately upon the signing of the contract and has the ability to draw down additional funds against the remaining $5 million equity credit line at 30-day intervals if needed, over a two-year period, subject to meeting certain conditions prior to request for funding. The equity will be in the form of convertible preferred stock at a stated discount from the market price calculated at the time of conversion and carries an 8% dividend payable in cash or stock at the company's option. Rash stated: "This transaction marks an important event in the company's history, in that we can now focus on taking our technology onto the commercialization phase. "The company intends to use the funding in four principal areas. To actively market our existing 100%-silicon balloon catheter line of which we have 10 FDA approved products; secondly to accelerate the development of the company's guideware micro-filter technology; thirdly to expand the OmniCath(R) clinical trials from the on-going peripheral trials into the AV Fistula trials, and lastly, to continue discussions with strategic partners that can assist in commercially advancing our technologies." American BioMed utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The company's products include 100%-silicone-based catheters, through its Cathlab subsidiary; the Evert-O-Cath(TM), a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCath, an atherectomy catheter designed to remove athersclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The company has over 25 patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be an over $10 billion industry. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, the results of financing efforts, the effect of the company's accounting policies, and other risks detailed in the company's Securities and Exchange Commission filings. CONTACT: American BioMed Inc. Steven B. Rash, 281/367-3895 or Coffin Communications Matt Lepo, (Investor Relations) 818/789-0100 or Coffin/Mottola Communications Christi Mottola, (Press Relations) 714/851-1109 KEYWORD: TEXAS BW1091 MAY 07,1998 Not bad for a microcap company!